Allo-Immunotherapy (AIM-001): A New Era in Localized Immunotherapy
Broad application across solid tumor types and disease stages.
AIM-001 induces the transplant rejection immune response at the site of the tumor.
AIM-001 makes checkpoint immunotherapy work better for more patients. Turns cold tumors hot.
Localized delivery of AIM-001 during biopsy or tumor resection surgery.
Improve outcomes for patients with advanced solid tumors and limited therapeutic options. Help checkpoint immunotherapy portfolios work better for more patients. Majority of patients do not respond to checkpoint immunotherapy – AIM-001 unlocks the potential.
AIM-001 is simple, localized cell-based therapy implanted at the primary or metastatic tumor site during biopsy or resection surgery. AIM-001 baits the immune system locally and activates the immune system systemically to sensitize patients to checkpoint immunotherapy, resulting in increased response rates, durability, and expanded patient eligibility.
